GrB-Fc-IT4 / AbBC Therapies - LARVOL DELTA

Targeting chemo-resistant ovarian cancer with a first-in-class, first-in-human immune-oncology agents containing granzyme B (AACR 2024) - "In the past decades, there have been several developments in front-line maintenance therapy including bevacizumab or PARP inhibitors...Our laboratory has developed several fully human granzyme B (GrB) based fusion proteins against key OC targets including folate receptor 1 (GrB-Fc-mov018) and fibroblast growth factor-inducible 14 (GrB-Fc-IT4) which retain high specificity of the targeting agent, combined with the GrB specific activity, a pro-apoptotic mechanism of action, and a robust in vivo efficacy...Our results suggest that the mechanism of resistance developed to conventionally used chemotherapeutic agents such as Paclitaxel, Doxorubicin, Cisplatin or Mitomycin do not confer resistance to GrB-based constructs. Hence, we speculate that GrB-based constructs could be an effective therapy in OC patients with immune-excluded tumors that have developed resistance to conventional treatment. Research conducted, in part, by the Clayton Foundation for Research."

First-in-human • IO biomarker • P1 data • Lung Cancer • Melanoma • Oncology • Ovarian Cancer • Solid Tumor • FOLR1 • GZMB